WO2019126341A3 - Compositions and methods for the treatment of bacterial infections - Google Patents

Compositions and methods for the treatment of bacterial infections Download PDF

Info

Publication number
WO2019126341A3
WO2019126341A3 PCT/US2018/066529 US2018066529W WO2019126341A3 WO 2019126341 A3 WO2019126341 A3 WO 2019126341A3 US 2018066529 W US2018066529 W US 2018066529W WO 2019126341 A3 WO2019126341 A3 WO 2019126341A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
bacterial infections
compositions
methods
albumin protein
Prior art date
Application number
PCT/US2018/066529
Other languages
French (fr)
Other versions
WO2019126341A2 (en
Inventor
Suzanne AKERS-RODRIGUEZ
James M. Balkovec
Daniel C. BENSEN
Timothy Blizzard
Allen Borchardt
Thomas P. Brady
Zhi-yong CHEN
Quyen-Quyen Thuy Do
Simon DOEHRMANN
Wanlong Jiang
Thanh Lam
James LEVIN
Jeffrey B. LOCKE
Alain Noncovich
Leslie W. TARI
Original Assignee
Cidara Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics, Inc. filed Critical Cidara Therapeutics, Inc.
Publication of WO2019126341A2 publication Critical patent/WO2019126341A2/en
Publication of WO2019126341A3 publication Critical patent/WO2019126341A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions and methods for the treatment of bacterial infections including conjugates containing an albumin protein or an albumin protein-binding peptide covalently linked to one or more monomers of cyclic heptapeptides or one or more dimers of cyclic heptapeptides. In particular, conjugates can be used in the treatment of bacterial infections caused by Gram-negative bacteria.
PCT/US2018/066529 2017-12-20 2018-12-19 Compositions and methods for the treatment of bacterial infections WO2019126341A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762608342P 2017-12-20 2017-12-20
US62/608,342 2017-12-20
US201862696771P 2018-07-11 2018-07-11
US62/696,771 2018-07-11
US201862725099P 2018-08-30 2018-08-30
US62/725,099 2018-08-30

Publications (2)

Publication Number Publication Date
WO2019126341A2 WO2019126341A2 (en) 2019-06-27
WO2019126341A3 true WO2019126341A3 (en) 2019-09-12

Family

ID=66995067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/066529 WO2019126341A2 (en) 2017-12-20 2018-12-19 Compositions and methods for the treatment of bacterial infections

Country Status (1)

Country Link
WO (1) WO2019126341A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112522378B (en) * 2020-11-18 2023-10-31 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） Kit for detecting MCR gene, detection method and application thereof
CN113332238A (en) * 2021-06-09 2021-09-03 四川恒通动保生物科技有限公司 Preparation method of compound solution with gamithromycin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
US20060014820A1 (en) * 2004-07-16 2006-01-19 Burstein Sumner H Lipid-amino acid conjugates and methods of use
US20150306238A1 (en) * 2012-12-12 2015-10-29 The Regents Of The University Of Michigan Bacteria targeting nanoparticles and related methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
US20060014820A1 (en) * 2004-07-16 2006-01-19 Burstein Sumner H Lipid-amino acid conjugates and methods of use
US20150306238A1 (en) * 2012-12-12 2015-10-29 The Regents Of The University Of Michigan Bacteria targeting nanoparticles and related methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem compound [online] 25 March 2005 (2005-03-25), "PubChem compound Summary CID4868 | C56H98N16O13", XP055637262, retrieved from NCBI Database accession no. CID4868 *

Also Published As

Publication number Publication date
WO2019126341A2 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
WO2018128826A8 (en) Compositions and methods for the treatment of bacterial infections
WO2018229236A3 (en) Compositions comprising bacterial strains
WO2017049233A3 (en) Lysin polypeptides active against gram-negative bacteria
WO2017218922A3 (en) Compositions and methods for the treatment of bacterial infections
WO2016033225A3 (en) Antibodies, compositions, and uses
WO2017017631A3 (en) Antibacterial therapeutics and prophylactics
BR112016002614B8 (en) Immunocytokine and pharmaceutical composition
MX2016015218A (en) Macrocyclic broad spectrum antibiotics.
EA201890320A1 (en) ANTIBODY MOLECULES THAT BIND CD79
WO2013025834A3 (en) Compositions and methods related to antibodies to staphylococcal protein a
MX2017010628A (en) Novel proteins specific for pyoverdine and pyochelin.
EA201992175A1 (en) COMPOSITIONS AND METHODS INCLUDING PROBIOTIC MOLECULES
WO2017066719A3 (en) Hu specific interfering agents
MX2018006190A (en) Macrocyclic broad spectrum antibiotics.
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
MX2018006199A (en) Macrocyclic broad spectrum antibiotics.
WO2019014260A3 (en) Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof
WO2015123493A3 (en) Compositions and methods for modulatuion of immune response
WO2019126341A3 (en) Compositions and methods for the treatment of bacterial infections
CA3010564A1 (en) An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition
PH12019501904A1 (en) Macrocyclic broad spectrum antibiotics
MX2016007626A (en) Antimicrobial peptide and uses thereof.
MX2016001927A (en) Linear peptide antibiotcs.
WO2020014501A8 (en) Compositions and methods for the treatment of bacterial infections
WO2017002049A3 (en) Conserved chaperone domain for type vi secretion system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18893210

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18893210

Country of ref document: EP

Kind code of ref document: A2